Nimodipine Patent Expiration
Nimodipine is used for improving neurological outcomes and reducing ischemic deficits in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms. It was first introduced by Bayer Pharmaceuticals Corp
Nimodipine Patents
Given below is the list of patents protecting Nimodipine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nymalize | US10342787 | Non-aqueous liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US10576070 | Non-aqueous liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US11207306 | Non-aqueous liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US11413277 | Non-aqueous liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US11517563 | Liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US11759457 | Liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US11806338 | Non-aqueous liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US12186308 | Non-aqueous liquid nimodipine compositions | Apr 16, 2038 | Azurity |
| Nymalize | US8517997 | Dispenser for medicaments and method and apparatus for making same |
May 14, 2024
(Expired) | Azurity |
| Nymalize | US7070581 | Dispenser for medicaments and method and apparatus for making same |
Jun 23, 2023
(Expired) | Azurity |
Nimodipine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Nimodipine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months | Fondation Ophtalmologique Adolphe de Rothschild | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |